olutegravir (as sodium) / lamivudine/ tenofovir disoproxil fumarate 50 mg/ 300 mg/ 300 mg tablets (Macleods Pharmaceuticals Limited), HA713

Steps taken following Prequalification of [HA713 trade name]*

This document will only list changes endorsed by WHO Prequalification Team – Medicines that affect the WHOPAR.

Changes	WHOPAR parts affected	Date
Change in the FPP shelf-life involving extension	4	July 2020
Addition of FPP manufacturing and testing site	3	April 2021
Addition of an extension to the existing approved manufacturing site	3	July 2021
Addition of FPP primary packaging type	3, 4	December 2021
Addition of FPP manufacturing and testing site	3	January 2022
Change in the FPP shelf-life involving extension	4	January 2023
Addition of FPP manufacturing and testing site	3	July 2023

Page 1 of 1

^{*} Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.